Summary of therapy recommendations for fungal infection in the non-neutropenic critical-care patient: A multidisciplinary view;Resumen de las recomendaciones terapéuticas para infecciones fúngicas en el paciente crítico no neutropénico: Una visión multidisciplinar

Farmacia Hospitalaria

Volumn 29, Issue 4, 2005, Pages 283-289

  Garnacho Montero, José ^a   Leon Gil C ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; DEOXYCHOLIC ACID; FLUCONAZOLE;

ASPERGILLUS; CANDIDA; CANDIDIASIS; HUMAN; MYCOSIS; NEUTROPENIA; NONHUMAN; PRACTICE GUIDELINE; REVIEW;

EID: 27744451976     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1130-6343(05)73677-1     Document Type: Review

References (49)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1564-54.
2. Büchner T, Fegeler W, Bernhardt H, Brockmeyer N, Duswald KH, Herrmann M. Treatment of severe candida infections in high-risk patients in Germany: Consensus formed by a panel of interdisciplinary investigators. Eur J Clin Microbiol Infect Dis 2002; 21: 337-52.
3. Pappas PG, Rex JH, Sobel JD, Filler SD, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89.
4. Garnacho Montera J, León Gil C, Almirante Grajera B, Álvarez Lerma F, Cuenca Estrella M, García Rodríguez JA, et al. Recomendaciones terapéuticas en el paciente crítico no neutropénico. Conferencia de Consenso. Conclusiones. Med Intensiva Supl 2005; 3 (1): 43-52.
5. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol 2000; 21: 510-5.
6. Marchetti O, Bille J, Fluckiger U, Eggimannn P, Ruef C, Garbino J, et al. Epidemiology of candidemia in Swiss tertiary care hospitals. Secular trends, 1991-2000. Clin Infect Dis 2004; 38: 311-20.
7. Olaechea PM, Palomar M, León-Gil C, Álvarez-Lerma F, Jorda R, Nolla-Salas J, et al. Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis 2004; 23: 323-30.
8. Nolla-Salas J, Sitges-Serra A, León-Gil, Martínez González J, León Regidor MA, Ibáñez Lucía P, et al. Candidemia in non-neutropenic critically ill patients: Analysis of prognostic factors and assessment of systemic antifungal therapy. Intensive Care Med 1997; 23: 23-30.
9. Charles PE, Doise JM, Quenot JP, Haube H, DAlle P, Chavanet P, et al. Candidemia in critically ill patients: Difference of outcome between medical and surgical patients. Intensive Care Med 2003; 29: 2162-9.
10. Vincent JL, Anaissie E, Bruining H, Demajo W, el-Ebiahri M, Haber J, et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 1998; 24: 206-16.
11. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686-93.
12. Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, et al. Clinical significacne of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29: 1402-7.
13. Rex J, Bennett J, Sugar A, Pappas P, van der Horst C, Edwards J, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331: 1325-10.
14. Anaissie EJ, Daouiche RO, Abi-Said D, Uzun O, Mera J, Gentry LO, et al. Magement of invsive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature, Clin Infect Dis 1996; 23: 964-72.
15. Phillips P, Shafran S, Garber G, Rotstein C, Smaill F, Fong I, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur J Clin Microbiol Infect Dis 1997; 16: 337-45.
16. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2001; 36: 1221-8.
17. Cuenca-Estrella M, Rodríguez D, Almirante B, Morgan J, Planes AM, Almela M, et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance program, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005; 55: 194-9.
18. Mora-Duarte J, Betts R, Rotstein R, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericim B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
19. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH. The Epidemiology of Nephrotoxicity Associated with Conventional Amphotericin B Therapy. Am J Med 2001; 111: 528-34.
20. Walsh T, Hiemenz J, Seibel N, Perfect J, Horwith G, Lee L, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383-96
21. Walsh T, Finberg R, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764-71.
22. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402.
23. Ostrosky-Zeichner L, Man KA, Cohen SH. Amphotericin B: time for a new "gold standard". Clin Infect Dis 2003; 37: 415-25.
24. Kullberg BJ, Pappas P, Ruhnke M, Viscoli C, Cleary JD, Rubinstein E, et al. Voriconazole compared with strategy of amphotericin B followed by fluconazole for treatment of candidemia in non-neutropenic patients. Clin Microbiol Infect 2004; 10: 41S.
25. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3: 685-702.
26. Álvarez-Lerma F, Nolla-Salas J, León C. Candiduria in critically ill patients admitted to the intensive care units. Intensive Care Med 2003; 29: 1069-76.
27. Tambyah PA, Maki DG. Catheter-associated urinary tract infection in rarely symptomatic: a prospective study of 1497 catheterized patients. Arch Intern Med 2000; 160: 678-82.
28. Sobel JD, Kauffman CA, McKinsey D, Zervos M, Vazquez JA, Karchmer AW, et al. Candiduria: A randomized, double-blind study of treatment with fluconazole and placebo. Clin Infect Dis 2000; 30: 19-24.
29. Drew RH, Arthur RR, Perfect JR. Is it time to abandon the use of amphotericin B bladder irrigation? Clin Infect Dis 2005; 40: 1465-70.
30. Agustin J, Lacson S, Rafalli J, Aguro M, Wormser G. Failure of a lipid amphotericin B preparation to eradicate candiduria: preliminary findings based on three cases. Clin Infect Dis 1999; 29: 686-7.
31. Rello J, Esandi ME, Díaz E, et al. The role of Candida spp isolated from bronchoscopic simples samples in non-neutropenicci patients. Chest 1998; 114: 146-9.
32. El-Ebiary M, Torres A, Fabregas N, et al. Significance of the isolation of Candida species from respiratory samples in critically ill non-neutropenic patients. Am J Resp Crit Care Med 1997; 156: 583-90.
33. Azoulay E, Cohen Y, Zahar JR, Garrouste-Oregeas M, Adrie C, Moine P, et al. Practices in non-neutropenicci ICU patients with Candida-positive airway specimens. Intensive Care Med 2004; 30: 1384-9.
34. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220: 751-8.
35. Piarroux R, Grenoullet F, Balvay P, Tran V, Blasco G, Millon L, et al. Assessment of pre-emptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004; 32: 2443-9.
36. Rocco TR, Reinert SE, Simms HH. Effects of fluconazole administration in critically ill patients. Arch Surg 2000; 135: 160-5.
37. Wey SB, Mon M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital acquired candidemia. A matched case-control study. Arch Intern Med 1989; 149: 2349-53.
38. Dimopopulos G, Piagnerelli M, Berre J, Eddafali B, Salmon I, Vincet JL. Disseminated aspergillosis in intensive care unit patients: an autopsy study. J Chemother 2003; 15: 71-5.
39. Meersseman W, Vandeecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Wijngaerden EV. Invasive aspergillosis in critically ill patients without malignancy. Am J Resp Crit Care Med 2004; 170: 621-5.
40. Ascioglu S, Rex JH, de Pauw B, Bennet JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplant: an international consensus. Clin Infect Dis 2002; 34: 7-14.
41. Rello J, Esandi ME, Mariscal D, Gallego M, Domingo C, Vallés J. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: report of eight cases and review. Clin Infect Dis 1998; 26: 1473-5.
42. Dimopopulos G, Piagnerelli M, Berre J, Eddafali B, Salmon I, Vincet JL. Disseminated aspergillosis in intensive care unit patients: an autopsy study. J Chemother 2003; 15: 71-5.
43. Hartemink KJ, Paul MA, Spijkstra JJ, Girbes AR, Polderman KH. Immunoparalysis as a cause for invansive aspergillosis? Intensive Care Med 2003; 29: 2068-71.
44. Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, León C, Álvarez-Lerma F, Nolla-Salas J, et al. Isolation of Aspergillus spp from the respiratory tract in critically ill patients: risk factors, clinical presentation, and outcome. Crit Care 2005; 9: R191-R199.
45. Denning DW, Hostetler JS, Kauffman CA, Pappas P, et al. NIAID Mycoses Study Group Multicenter Trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97: 22-5.
46. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
47. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen, FB, for the Caspofungin Salvage Aspergillosis Study Group. Efficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy. Clin Infect Dis 2004; 39: 1563-71.
48. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797-802.
49. Cuenca-Estrella M. Combinations of antifungal agents in therapy-what value are they? J Antimicrob Chemother 2004; 54: 854-69.